ST. LOUIS, Oct. 7 /PRNewswire-FirstCall/ -- GenoMed, Inc., a Next Generation DM(TM) (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that it will offer its patent-pending broad spectrum viral antidote to the nation during this coming flu season this fall and winter.Because of difficulties that a major pharmaceutical company has experienced at a British factory, nearly half of the flu vaccine doses destined for the U.S. will not be delivered in time for this year´s flu season. U.S. health authorities have already begun planning how to ration existing flu vaccine doses.

GenoMed has applied for patent protection on the use of a class of blood pressure medications in viral diseases, such as the flu. This is a totally novel approach. There is no shortage of these medications worldwide.

The Company has had 100% success in treating a small number of normal, immunocompetent patients suffering from West Nile virus encephalitis during the past two summers, including the elderly. GenoMed´s first case series of eight patients was published in July, 2004 in Current Topics in Medicinal Chemistry, a peer-reviewed medical journal.

Both the White House Office of Science Technology & Policy and the Department of Homeland Security have expressed interest in GenoMed´s potential broad-spectrum viral antidote. GenoMed will be meeting during October with the National Institute of Allergy and Infectious Diseases (NIAID) to discuss further testing of its approach against viral diseases, including influenza.

About GenoMed

GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. GenoMed´s influenza trial will be Internet-based, like its current West Nile virus trial. Click here to enroll in the flu trial: http://www.b2i.us/external.asp?b=571&id=377&from=pi To enroll in GenoMed´s West Nile trial, click on the "West Nile trial" link at GenoMed´s website, http://www.genomed.com .

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.´s (the Company´s) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment will be as effective against influenza as it has been against a small number of patients with West Nile virus encephalitis; (b) whether our server will hold up to heavy demand; (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

---

Source: GenoMed, Inc.